AdaptHealth CFO Outlines Growth Strategy: Recurring Revenue, Faster Patient Onboarding, and Major West Coast Expansion
AdaptHealth (NASDAQ: AHCO), a leading home medical equipment provider, is capitalizing on underdiagnosis in the sleep apnea market and operational efficiencies to drive recurring revenue and market share gains, Chief Financial Officer Jason Clemens told investors this week.
Clemens pointed to a significant diagnosis gap as a core growth driver. With an estimated 33-34 million Americans suffering from obstructive sleep apnea (OSA), only about 20% are currently diagnosed and receiving treatment. "The awareness wave from wearables and home sleep tests is creating record wait times at sleep labs," Clemens noted, signaling sustained demand for the company's CPAP devices and services.
The company's financial model hinges on this installed base. Using Medicare as an example, Clemens described a 13-month rental period paying roughly $60 monthly for adherent patients, followed by a capped period through month 60. The real engine, however, is the resupply business for masks, tubes, and cushions—a "razor blade" model yielding average orders of $200. AdaptHealth outperforms the industry average by resupplying patients close to three times annually, versus an industry standard near two, aided by adherence monitoring tech and multi-channel outreach through its app.
Adherence rates, critical for reimbursement, are another focal point. Clemens said AdaptHealth's rate exceeds 80%, compared to an industry average just over 70%, supported by hundreds of sleep coaches and standardized workflows. He also observed an intriguing trend: patients on GLP-1 medications, like those for weight loss and diabetes, are showing better adherence, providing a modest lift to overall rates.
Perhaps the most striking operational improvement is in speed. The company has slashed the average time to set up a CPAP patient from over 17 days to just nine. Clemens cited prior authorization delays and patient contact as key bottlenecks previously. The fix involves tech-driven solutions: QR codes in doctors' offices for instant app downloads and AI chatbots that efficiently route patients based on capacity across its nearly 700 locations.
On the expansion front, Clemens detailed a "major" West Coast infrastructure project tied to a new capitated contract. The build-out includes approximately 30 new locations, hundreds of vehicles, and about 1,200 new hires. Revenue has already begun to flow, and the company has raised its financial expectations for the contract due to the infrastructure's readiness. This contract covers sleep, respiratory, and durable medical equipment (DME) like beds and wheelchairs.
The company is also deepening its relationship with major payers. Its capitated agreement with Humana now covers HMO Medicare Advantage patients in 33 states and D.C., with 100% of that population "ready" for service. Clemens described a "halo effect" from this partnership, boosting its preferred provider status for Humana's PPO business.
Regulatory clarity provides a tailwind. Clemens noted that CMS's recently finalized competitive bidding rules for 2028 exclude AdaptHealth's core categories of sleep, respiratory, and DME. While diabetes (including CGMs), ostomy, and urology are included, the CFO framed this as an opportunity. CMS projections suggest the number of DME suppliers distributing CGMs to Medicare patients could plummet from nearly 2,000 to "10 or less." As the number two player in Medicare CGM distribution, AdaptHealth is poised to capture significant share.
Financially, the sleep and respiratory segments remain highly profitable, generating adjusted EBITDA margins in the high 20% range. The company's strategy appears to be paying off, with Clemens reporting record patient census and a setup quarter in 2026 that is expected to set new records.
Investor & Analyst Reactions
Michael R., Portfolio Manager at a Healthcare Fund: "Clemens provided a masterclass in how to build a scalable, service-driven HMO model. The 9-day setup time is a massive competitive moat. It directly addresses physician pain points and drives referrals. The capitated contract growth, especially out West, shows they're executing on the land-and-expand strategy we invested in."
Dr. Sarah Chen, Pulmonologist & Sleep Specialist: "From the clinician side, the 'easy button' concept is real. When I refer a patient, I need to know they'll get set up quickly and supported properly. AdaptHealth's app and coach network directly improve patient compliance, which is the single biggest challenge in sleep medicine. Their data on GLP-1 patients is fascinating and warrants further study."
David K., Retail Investor & CPAP User: "Faster setups? Great. More revenue for them? Sure. But let's talk about the $200 resupply kits every few months. This 'razor blade' model feels like being locked into a subscription for your own breathing. They boast about adherence tech—is that for patient health, or just to guarantee their reimbursement? The system feels geared toward perpetual billing."
Lisa Wang, Medical Devices Equity Analyst: "The strategic takeaways are clear: AdaptHealth is shifting from a pure equipment play to a tech-enabled service platform. The margins speak for themselves. The exclusion from competitive bidding for their core products removes a major overhang. The real test will be integrating the West Coast expansion smoothly and proving the economics of these large capitated contracts over the long term."